• EUR 47 million committed by fund initiators Ascenion and Goethe-University together with the European Investment Fund (EIF), Evotec, and other investors
• Focus on high-potential, early-stage life-science start-ups and projects, sourced from Ascenion’s and Innovectis’ partner institutions and other European academic institutions
• 15 + 5 years timeframe enables the partners – and the institutions they represent – to participate in future profits
  
   

25 August 2021, Munich – Cardior Pharmaceuticals has closed a Series B financing round totalling EUR 64 million (USD 76 million). The round was led by…

Initiation of the IMAGE1NE Phase 1/2 clinical study of TK-8001, a TCR-T cell therapy for MAGE-A1 positive solid tumors, in Q4 2021

BioVaria Startup Awards go to iRASP Therapeutics and OrganoTherapeutics

This year’s BioVaria is digital and takes place exclusively online from the 26 to 28 April 2021.

• T-knife’s proprietary humanized mouse platform (HuTCR) T-cell Receptors expected to provide superior affinity/specificity properties
• Series A round led by Versant Ventures and RA Capital Management, with strong participation from seed investors Andera Partners and BIVF

Ascenion and Innovationsstarter Fonds Hamburg acquire equity in Hamburg start-up – innovative therapeutic approach enters clinical testing

Lead liver disease candidate to enter clinical trials this year

New drug delivery system to enable needle-free application of drugs

Ascenion’s portfolio company Berlin Cures has initiated a Phase IIa clinical study with its lead compound BC 007. The two-armed, randomized,…

BioVaria Start-up Awards go to ISD Immunotech and Mindpax.me
13 May 2019, Munich, Germany – The 12th BioVaria welcomed over 250 life-science…

Simultaneously Closes Strategic Growth Investment from Ampersand Capital to Create a Leading Provider of Genomic and Cell and Tissue Analysis Products…

BioVaria brings together Europe’s top scientists and technology transfer professionals with potential licensees and investors from the international…

Gramibactin is an iron-binding molecule of the siderophore family. It occurs naturally in certain plant-associated bacteria where it helps secure the…

Technology sneak peek from Ascenion: Seven breakthrough life-science inventions                                      

12 March 2019, Munich, Germany…

This year’s Annual Meeting of TechnologieAllianz, Germany’s association for knowledge and technology transfer (KTT) will take place on 20-21 March…

Ascenion Negotiated Additional Licence Agreement between Helmholtz Zentrum München and Medigene

9 January 2019, Munich – The Helmholtz Zentrum…

Boost for the first new tuberculosis vaccine in nearly 100 years 

21 August 2018, Munich – Ascenion GmbH, the technology transfer partner of the…

Phase I study initiated with candidate against multidrug-resistant germs 

6 June 2018, Munich – The Leibniz Institute for Natural Product Research…

This year’s BioVaria was the event in 2018 for early-stage, life-science European startups to connect with investors, with a record number of company…

Startup Awards go to OPSYON and LIfT Biosciences

26 April 2018, Munich, Germany – Over 250 innovative minds gathered in Munich on April 23-24 for the…

BioVaria brings together Europe’s top scientists and technology transfer professionals with potential licensees and investors from the international…

Technology sneak peek from Ascenion: Five breakthrough life-science inventions

9 March 2018, Munich, Germany – On 23–24 April 2018, decision makers…

Eye-to-eye networking, acquiring deeper knowledge, sharing experiences, keeping informed about new developments – these are the aims of the TT…

Making cancer surgery more precise

23 October 2017, Munich – SurgVision BV, a spin-off from the Helmholtz Zentrum München, has been acquired by…

9 October 2017, Munich – Last week Ascenion GmbH and the Medical University of Innsbruck launched their cooperation with a joint kick-off event. The…

BioVaria Spin-off Awards go to Captain T Cell and Provirex

24 May 2017, Munich, Germany – On 22–23 May 2017, over 180 innovative minds gathered in…

Unique RNA-based approach for the treatment of heart diseases

11 May 2017, Munich – Cardior Pharmaceuticals has completed a EUR 15 million Series A…

Technology Sneak Peek from Ascenion: Human T-cell receptors for cancer therapy

4 April 2017, Munich, Germany – On 22-23 May 2017, dealmakers from…

A consortium of nine partners from five European countries, led by the Helmholtz Zentrum München, will work together with a transdisciplinary approach…

OMEICOS Therapeutics, a spin-off from the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), announced the first closing…

Tubingen (Germany), January 05, 2017 – HepaRegeniX GmbH, a new Biotech company developing innovative treatments for liver diseases, announced today…

Berlin Cures, one of Ascenion’s investment portfolio companies, has announced the start of a clinical trial with its lead candidate BC007. The Phase I…

19 September 2016, Munich – Ascenion GmbH, the technology transfer partner of the Max Delbrück Center for Molecular Medicine in the Helmholtz…

BioVaria Spin-off Awards go to Charité spin-off and Braingineering Technologies

19 May 2016, Munich, Germany – Dealmakers and investors from the…

Cancer-fighting gene therapy

Ascenion unveils technology highlights: New approaches for the treatment of neurodegenerative disorders and glioblastoma

BioVaria is designed for dealmakers and investors from the global life-science sector responsible for identifying, licensing or funding break-through…

Flexible funds from technology transfer

21 December 2015, Berlin and Munich - ‘VONVENDI [von Willebrand factor (Recombinant)]’, the new drug from Baxalta Incorporated, a global…

Recent Publication in Key Scientific Journal Supports amcure’s Therapeutic Approach in Cancer

Ascenion takes equity in the MHH start-up Zellkraftwerk